Mode
Text Size
Log in / Sign up
Phase 4 N=168 Randomized Quadruple-blind Treatment

Treatment of Severe Childhood Aggression (The TOSCA Study)

Attention Deficit Disorder With Hyperactivity

Enrolled (actual)
168
Serious AEs
0.0%
Results posted
Apr 2016
Primary outcome: Primary: NCBRF-TIQ D-Total Score — 43.5; 42.1; 24.9; 25.9 units on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Methylphenidate HCl (Drug); Risperidone (Drug); Parent Management Training (PMT) (Behavioral); Placebo (Drug)
Age
Pediatric · 6+ yrs
Sex
All
Sponsor
Michael Aman
Primary completion
Nov 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
NCBRF-TIQ D-Total Score
43.5; 42.1; 24.9; 25.9; 22.4; 17.1

Summary

This study will determine the safety and effectiveness of two medications for treating aggression in children with attention deficit hyperactivity disorder (ADHD).

Eligibility Criteria

Inclusion Criteria

  • DSM-IV diagnosis of ADHD, any subtype
  • DSM-IV diagnosis of a disruptive behavior disorder, including CD or ODD
  • Evidence of serious physical aggression, as rated on the Overt Aggression Scale-Modified, and as determined by parent or guardian ratings on the NCBRF D-Total Score. In addition, the blinded clinician must assign a clinical global impressions severity score of 4 or greater for aggression.
  • Prior to random assignment, participants must be free of all psychotropic medicines for 2 weeks for most drugs (such as most antidepressants, alpha agonists, beta blockers, anxiolytics, mood stabilizers, and antihistamines), and 4 weeks for depot antipsychotics and fluoxetine.

Exclusion Criteria

  • Full-scale IQ below 71
  • Pregnancy or a history of seizure disorder or other neurological or medical disorders for which medication may present a considerable risk
  • Abnormal liver function
  • Pervasive developmental disorder, schizophrenia or other psychotic disorders, or eating disorders
  • Currently taking other psychotropic medications from which discontinuation would present a significant risk. Participants may not discontinue a satisfactory medication to participate.
  • Presence or history of major depressive disorder
  • Diagnosis of bipolar disorder
  • A hypomanic/biphasic score of 36 or greater as rated by child's parent on the General Behavior Inventory and confirmed by clinician as indication of mood disorder
  • Active substance abuse disorder or lack of control of substance use that does not allow for safe medication administration
  • Evidence of current child abuse or neglect
  • History of suicide attempt in the past year or current suicidal ideation with plan and/or intent
  • Family history of type II diabetes in two or more first degree relatives, defined as biological parents and/or full biological siblings
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00796302). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search